These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

927 related items for PubMed ID: 27169565

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis.
    Peterson SC, Barry AR.
    Curr Diabetes Rev; 2018; 14(3):273-279. PubMed ID: 28413990
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials.
    Al Yami MS, Alfayez OM, Alsheikh R.
    Heart Lung Circ; 2018 Nov; 27(11):1301-1309. PubMed ID: 29887418
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.
    Storgaard H, Cold F, Gluud LL, Vilsbøll T, Knop FK.
    Diabetes Obes Metab; 2017 Jun; 19(6):906-908. PubMed ID: 28105738
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper respiratory tract infection among patients with type 2 diabetes: a network meta-analysis].
    Li ZX, Wu SS, Yang ZR, Zhan SY, Sun F.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Jun 18; 48(3):454-9. PubMed ID: 27318907
    [Abstract] [Full Text] [Related]

  • 30. GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Banerjee M, Pal R, Mukhopadhyay S, Nair K.
    J Clin Endocrinol Metab; 2023 Jun 16; 108(7):1806-1812. PubMed ID: 36800286
    [Abstract] [Full Text] [Related]

  • 31. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
    Kramer CK, Ye C, Campbell S, Retnakaran R.
    JACC Heart Fail; 2018 Oct 16; 6(10):823-830. PubMed ID: 30196071
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.
    Guo X, Yang Q, Dong J, Liao L, Zhang W, Liu F.
    Clin Drug Investig; 2016 Jun 16; 36(6):433-41. PubMed ID: 26979594
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
    Wong SY, Lee ARYB, Sia AHJ, Wo YJ, Teo YH, Teo YN, Syn NL, Ong CC, Teo LL, Yeo TC, Poh KK, Kong WK, Wong RC, Sia CH.
    Cardiovasc Drugs Ther; 2024 Apr 16; 38(2):371-389. PubMed ID: 35819544
    [Abstract] [Full Text] [Related]

  • 36. Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis.
    Avgerinos I, Karagiannis T, Malandris K, Liakos A, Mainou M, Bekiari E, Matthews DR, Tsapas A.
    Diabetes Obes Metab; 2019 Jan 16; 21(1):188-193. PubMed ID: 30058208
    [Abstract] [Full Text] [Related]

  • 37. Impact of Heart Failure History at Baseline on Cardiovascular Effects of GLP-1 Receptor Agonists in Type 2 Diabetes: a Meta-analysis.
    Banerjee M, Maisnam I, Mukhopadhyay S.
    Cardiovasc Drugs Ther; 2024 Aug 16; 38(4):739-746. PubMed ID: 36696050
    [Abstract] [Full Text] [Related]

  • 38. Targeting the DPP-4-GLP-1 pathway improves exercise tolerance in heart failure patients: a systematic review and meta-analysis.
    Chen C, Huang Y, Zeng Y, Lu X, Dong G.
    BMC Cardiovasc Disord; 2019 Dec 23; 19(1):311. PubMed ID: 31870322
    [Abstract] [Full Text] [Related]

  • 39. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.
    Qin J, Song L.
    BMC Endocr Disord; 2022 May 12; 22(1):125. PubMed ID: 35546664
    [Abstract] [Full Text] [Related]

  • 40. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ.
    Circulation; 2017 Aug 29; 136(9):849-870. PubMed ID: 28847797
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.